Identification of Zika virus NS2B-NS3 protease and NS5 polymerase inhibitors by structure-based virtual screening of FDA-approved drugs
- PMID: 37528667
- DOI: 10.1080/07391102.2023.2242963
Identification of Zika virus NS2B-NS3 protease and NS5 polymerase inhibitors by structure-based virtual screening of FDA-approved drugs
Abstract
Zika virus (ZIKV) is a mosquito-borne human flavivirus responsible that causing emergency outbreaks in Brazil. ZIKV is suspected of causing Guillain-Barre syndrome in adults and microcephaly. The NS2B-NS3 protease and NS5 RNA-dependent RNA polymerase (RdRp), central to ZIKV multiplication, have been identified as attractive molecular targets for drugs. We performed a structure-based virtual screening of 2,659 FDA-approved small molecule drugs in the DrugBank database using AutoDock Vina in PyRx v0.8. Accordingly, 15 potential drugs were selected as ZIKV inhibitors because of their high values (binding affinity - binding energy) and we analyzed the molecular interactions between the active site amino acids and the compounds. Among these drugs, tamsulosin was found to interact most efficiently with NS2B/NS3 protease, as indicated by the lowest binding energy value (-8.27 kJ/mol), the highest binding affinity (-5.7 Kcal/mol), and formed H-bonds with amino acid residues TYRB130, SERB135, TYRB150. Furthermore, biotin was found to interact most efficiently with NS5 RdRp with a binding energy of -150.624 kJ/mol, a binding affinity of -5.6 Kcal/mol, and formed H-bonds with the amino acid residues ASPA665 and ASPA540. In vitro, in vivo, and clinical studies are needed to demonstrate anti-ZIKV safety and the efficacy of these FDA-approved drug candidates.Communicated by Ramaswamy H. Sarma.
Keywords: NS2B-NS3; NS5 RdRp; Zika virus; drug design; virtual screening.
Similar articles
-
Repurposing of antiparasitic drugs against the NS2B-NS3 protease of the Zika virus.J Biomol Struct Dyn. 2024;42(19):10101-10113. doi: 10.1080/07391102.2023.2255648. Epub 2023 Sep 25. J Biomol Struct Dyn. 2024. PMID: 37747074
-
The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection.Int J Mol Sci. 2024 Apr 16;25(8):4376. doi: 10.3390/ijms25084376. Int J Mol Sci. 2024. PMID: 38673962 Free PMC article. Review.
-
Elucidating the inhibitory mechanism of Zika virus NS2B-NS3 protease with dipeptide inhibitors: Insights from molecular docking and molecular dynamics simulations.PLoS One. 2024 Aug 8;19(8):e0307902. doi: 10.1371/journal.pone.0307902. eCollection 2024. PLoS One. 2024. PMID: 39116118 Free PMC article.
-
Mutational analyses, pharmacophore-based inhibitor design and in silico validation for Zika virus NS3-helicase.J Biomol Struct Dyn. 2024;42(19):9873-9891. doi: 10.1080/07391102.2023.2252929. Epub 2023 Sep 15. J Biomol Struct Dyn. 2024. PMID: 37712848
-
Exploiting the unique features of Zika and Dengue proteases for inhibitor design.Biochimie. 2019 Nov;166:132-141. doi: 10.1016/j.biochi.2019.05.004. Epub 2019 May 9. Biochimie. 2019. PMID: 31077760 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials